<DOC>
	<DOC>NCT00044044</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.</brief_summary>
	<brief_title>A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Inclusion criteria: The patient has a primary diagnosis of schizophrenia The patient has been hospitalized with acute or relapsing schizophrenia within 3 weeks of screening The patient has had a duration of illness of at least one year. The patient has a BPRS score of at least 42 at baseline and a score of at least 4 in two or more items of the positive symptom subcluster on the PANSS The patient is able to remain off antipsychotic medication for a 4 day washout period Exclusion criteria: The patient has had psychiatric hospitalizations other than current hospitalizations within 1 month prior to screening. The patient is considered treatment resistantSubstance abuseProlactin level of &gt; 200 ng/mL at baseline Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Latuda</keyword>
	<keyword>Lurasidone</keyword>
</DOC>